The European Renal Biopsy cDNA Bank (ERCB): A Multicenter Study for Disease Specific mRNA Expression Analysis in Human Kidney Biopsies

Dr. Anna Henger
Medizinische Poliklinik
Klinische Biochemie
Schillerstr. 42
80336 München
telephone: 089-5996841
fax: 089-5996860
prestype: Poster
presenter: Anna Henger

A. Henger, C. D. Cohen, D. Schlöndorff, M. Kretzler
Medizinische Poliklinik der LMU, Pettenkoferstr. 8a, 80336 München, for the ERCB Consortium

As a consequence of the current molecular advances gene expression analysis could become an important diagnostic tool in nephrology. The generation of a comprehensive renal cDNA biopsy bank will be a critical pre-requisite to test the diagnostic and prognostic value of this approach. To this end, an interdisciplinary European collaboration of renal research centers was initiated and the following protocol for the collection of cDNAs from microdissected renal biopsies has been established: In participating centers informed consent is obtained from patients undergoing routine diagnostic renal biopsy, clinical parameters are collected in a standardized data sheet and 10% of a renal biopsy cylinder is obtained for molecular analysis. Glomeruli and tubulo-interstitial segments are manually microdissected and mRNA expression analysis is performed. Currently, the biopsy material is analyzed for expression changes of candidate marker genes with a semi-automated 'real-time' RT-PCR system. Glomerular specific cDNAs are employed together with housekeeping mRNAs for quality control of the material obtained. Using this system, cDNAs of interest can be reproducibly quantified from as little as 1% of a microdissected glomerulus, enabling parallel quantification of up to 100 different cDNAs from one biopsy segment. Microdissection effectively separated glomeruli and tubulointerstitial compartments with no significant cross contamination.

The ERCB will allow expression analysis in defined human renal diseases for specific cDNAs of interest. In addition, correlation of mRNA expression pattern could reveal diagnostic and prognostic molecular markers, giving nephrologists a fundamentally novel kind of information to guide their patient care. Finally, complex molecular networks activated in human renal disease processes can be identified as potential novel targets for disease management.

Members of the ERCB:
A. McKinnon, P. A. J. Brown, A. Rees, Aberdeen; P. Mertens, J. Floege, Aachen; L. Gesualdo, F. P. Schena, Bari; M. Saleem, Bristol; M. Clarkson, H. R. Brady, Dublin; F. Strutz, G. Müller, Göttingen; M. Kuhlmann, H. Köhler Homburg/S.; J. K. Gerth, R. Fünfstück, G. Stein, Jena; M. P. Rastaldi, G. D'Amico, Milan; F. Delarue, J. D. Sraer, Paris; M. Fischereder, B. Krämer, Regensburg; R. Wütrich, St. Gallen; N. Braun, T. Risler, Tübingen; R. Oberbauer, D. Kerjaschki, Vienna; D. Mönks, C. Wanner, Würzburg.

  Abstract List

Abstracts * Speakers * Organizers * Home

Genetic Meetings